Company / Shareholders' Equity
Compass Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$125.2M
FY2024
5-year range
$39.9M / $181.6M
FY2020-FY2024
Trend
-15.7%
vs FY2023
Sector context
#165 of 213
Health Care
What the data says
Compass Therapeutics, Inc.'s shareholders' equity of $125M is lower than 77% of companies in the Health Care sector (FY2024). Declined from $182M to $125M over the past 2 years.
Based on SEC 10-K filings.
$125M in FY2024 with a 5-year CAGR of +61.9%.
Declined from $182M to $125M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.7%
- 5-Year CAGR
- +61.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 213This company $125.2M Sector average $2.5B
▼
-95.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +61.9%, indicating consistent growth.
- In FY2024, shareholders' equity decreased 15.7% year-over-year.
- Ranks #165 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $125.2M | -15.7% |
| FY2023 | $148.5M | -18.2% |
| FY2022 | $181.6M | +29.7% |
| FY2021 | $140.1M | +250.7% |
| FY2020 | $39.9M | +254.5% |
| FY2019 | $11.3M | +113.3% |
| FY2018 | -$84.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026